Fig. 6.

Therapeutic treatment with mitazalimab prolongs the survival of MB49 tumor-bearing mice and, combined with OVA peptide, also prolongs the survival of E.G7-OVA tumor-bearing mice—Mice (hCD40tg) were inoculated with 0.25 × 10⁶ MB49 cells s.c. and administered 100 µg mitazalimab or Ctr IgG p.t. or i.p. on day 7, 10 and 13 post-inoculation. a Frequency of survival throughout the study. Mice were sacrificed once their tumor volumes approached the ethical tumor volume limit of 2 cm³. Alternatively, the MB49 tumor-bearing mice were administered 100 or 300 µg mitazalimab i.p. on day 7, 10 and 13 post-inoculation and 24 h after the final dose, tumors were collected for flow cytometry, b frequency of granzyme B⁺ CD8⁺ T cells in the tumor, c frequency of CD44^hi CD62L⁻ CD8⁺ T cells in the tumor. Mice were inoculated with 1 × 10⁶ E.G7-OVA cells s.c. on one flank and administered 100 µg mitazalimab and/or 10 µg OVA peptide (SIINFEKL) s.c. on the other flank. The treatments were administered on the day of tumor inoculation and once more, 7 days later, d E.G7-OVA tumor growth throughout the study, e frequency of survival throughout the study. n = 9–10 per group in a; n = 8 per group in b–c; n = 10 per group in d–e. Statistical significance was analyzed by the log-rank test in a and e, and by Mann–Whitney U test in b and c. All error bars indicate ± SEM